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Dual RNA-Sequencing leverages established next-generation sequencing
(NGS)-enabled RNA-Seq approaches to measure genome-wide transcriptional changes
of both an infecting bacteria and host cells. By simultaneously investigating both
organisms from the same biological sample, dual RNA-Seq can provide unique insight
into bacterial infection processes and reciprocal host responses at once. However, the
difficulties involved in handling both prokaryotic and eukaryotic material require distinct,
optimized procedures. We previously developed and applied dual RNA-Seq to measure
prokaryotic and eukaryotic expression profiles of human cells infected with bacteria,
using in vitro Chlamydia-infected epithelial cells as proof of principle. Here we provide
a detailed laboratory protocol for in vitro dual RNA-Seq that is readily adaptable to any
host-bacteria system of interest.
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INTRODUCTION
The complex interplay of infecting bacteria with their eukaryotic host is key to understanding
pathogenesis and disease progression (Humphrys et al., 2013). Dual RNA-Seq is a powerful method
to investigate these infection dynamics. By simultaneously capturing expressed genes of both the
pathogen and the host, dual RNA-Seq can summarize the molecular interplay of bacterial infection
processes and the reciprocal host responses. We previously developed and applied dual RNA-Seq
to Chlamydia-infected eukaryotic cells as proof-of-principle (Humphrys et al., 2013). Dual RNA-
Seq has been also successfully applied to several other bacteria-host pairings (Camilios-Neto et al.,
2014; Avican et al., 2015; Baddal et al., 2015; Brogaard et al., 2015; Rienksma et al., 2015; Aprianto
et al., 2016; Westermann et al., 2016).
RNA-Seq has several benefits over other transcriptional profiling methods. Microarrays suffer
from high background noise, cross hybridization issues, and are typically restricted to known or
predicted mRNAs (Lister et al., 2008; Shendure, 2008; Wang et al., 2009; Oosthuizen et al., 2011).
The large size of eukaryotic genomes typically excludes the use of tiling arrays to measure antisense
RNA expression and other non-coding RNA transcripts; conversely, tag-based sequencing suffers
from partial coverage of transcripts by design (Bertone et al., 2004). These drawbacks are largely
alleviated by RNA-Seq-based methods, which enable genome-scale coverage, the measurement of
absolute expression levels, and minimal background signal (Marioni et al., 2008; Fu et al., 2009;
Kawahara et al., 2012). Furthermore, RNA-Seq can detect transcribed intronic and intergenic
regions, as well as post-transcriptional regulatory events such as alternative splicing and differential
isoform expression (Mortazavi et al., 2008; Kalam et al., 2017).
However, sequencingmixed prokaryotic and eukaryotic populations presents several challenges.
For example, bacterial RNAs can constitute <1% of the total RNA in an infected cell.
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Moreover, up to 98% of total RNA in an infected cell is
eukaryotic ribosomal RNA (rRNA), requiring rRNA depletion
or mRNA enrichment strategies to ensure sufficient non-rRNA
can be sequenced at reasonable cost (Giannoukos et al., 2012).
Additionally, traditional cell lysis techniques are often not
suitable for both eukaryotic and prokaryotic organisms at once.
Finally, the trade-off between the multiplicity of infection (MOI)
used and sequencing depth (cost) can lead to a mixed population
of infected and uninfected cells, which may bias results.
A complete dual RNA-Seq experiment comprises three
stages: (1) Total host-bacteria RNA extraction and purification;
(2) next-generation sequencing (NGS) of total RNA; and
(3) bioinformatic processing and statistical analysis of the
host-bacteria transcriptome. Here we present a laboratory
methodology for stage (1) of a typical in vitro dual RNA-Seq
experiment. The steps are described for host cell infection,
total host-bacteria RNA extraction and rRNA depletion, RT-PCR
quality control, and RNA quantification (Figure 1). This RNA
can then be used as input for stages (2) and (3) of the dual RNA-
Seq experiment. While we provide some general guidelines and
recommendations for NGS and data analysis, detailed pipelines
have been described in detail previously (Marsh et al., 2017).
The protocol has been optimized according to yield, time,
throughput, reproducibility, and quality, and is widely applicable
to diverse pairings of mammalian cell line and bacterial species.
Wherever possible, we routinely use commercially available kits
due to their reliability and reproducibility, however we have
carefully optimized the manufacturer’s instructions to suit this
dual RNA-Seq protocol.
Experimental Design
For dual RNA-Seq, a typical workflow includes RNA extraction,
eukaryotic, and prokaryotic rRNA depletion, library preparation,
sequencing, and analysis (Figure 1). However, a careful
assessment of experimental design is crucial before these steps
are attempted. The biological question(s) of interest is the
starting point, whether it is a hypothesis-driven process via
use of bacterial mutants and/or host cell knockout/knockdown
mutants, or a hypothesis discovery experiment that, for
example, examines organisms that are not amenable to genetic
manipulation. The questions under examination will influence
the RNA moieties to be investigated (e.g. mRNA, miRNA,
ncRNA etc.), appropriate controls, the MOI, any time points, the
total RNA quantity required, and sequencing depth.
The choice of organism, both host and bacteria, is central
to the question(s) of interest and will inform much of
the experimental design. Host cells should be selected for
their biological relevance in relation to the bacterium. The
identification of host differentially expressed genes (DEGs) or
isoforms relative to mock-infected controls is the standard
approach; additional controls should also be considered to
differentiate specific from non-specific host responses to the
bacterium. The choice of bacterium is dependent on the infection
system under study, and can be expanded to compare (host or
bacterial) transcriptional differences in the presence of different
bacterial species, virulent vs. avirulent strains, or mutant vs.
wild-type strains.
FIGURE 1 | Flow chart of the laboratory methodology for dual
RNA-Sequencing of bacteria and their host.
The ability of a dual RNA-Seq experiment to accurately
determine differential gene expression between conditions is
contingent on obtaining minimal biological and technical
variation, which can be addressed by managing the trade-off
between the number of replicates and sequencing depth (Auer
and Doerge, 2010; Yu et al., 2017). We suggest that at least three,
but preferably six, biological rather than technical replicates
should be included tominimize statistical error and providemore
biologically meaningful data; increasing sequencing depth is a
secondary priority (Oshlack et al., 2010). While a larger number
of replicates can become statistically unwieldy it will also enable
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a greater amount of variation to be captured, decreasing the
rate of Type I errors (false positives). RNA spike-ins and unique
molecular identifiers (UMI) can also be included to quantify
absolute RNA levels if this is of interest (Jiang et al., 2011; Parekh
et al., 2016).
As the transcriptional responses of bacteria and host are likely
to occur at different times and to different degrees, any time
points should be selected to capture each stage of the infection
process. At very early times of infection, there is likely to be
a limited quantity of bacterial RNA present, particularly when
low MOIs are used. To address this, we typically opt to increase
sequencing depth to ensure sufficient bacterial sequence reads are
obtained.
It is beneficial to predict the quantity of RNA required during
the experimental design stage, and this will be influenced by the
number of samples, conditions, replicates, and time-points, as
well as the sequencing technology used. It is important to note
that total RNA quantity will vary according to both biological
(sample type, cellular metabolism) and technical (cell lysis,
RNA purification) reasons. Additionally, enough RNA should be
available to complete the QC stages of the experiment, including
RT-PCR, agarose gel electrophoresis, and Bioanalyzer analysis.
At the sequencing stage, the method of library preparation will
dictate how much RNA is required, which usually lies within
the microgram to picogram range. However, a useful convention
is that more RNA input will require less amplification during
sequencing, resulting in superior library complexity. As a guide,
for mammalian cell culture-based dual RNA-Seq experiments,
one well of a six-well plate results in ∼100 ng of host RNA and
∼500 pg bacterial RNA.
A sequencing depth that addresses the project objectives is
essential and it is recommended that ∼5 × 108 host reads and
>1 × 106 bacterial reads are required for adequate coverage
(Toung et al., 2011; Westermann et al., 2012). To achieve this
will depend on the organisms under investigation, but here we
present the calculations for aChlamydia-infected human host cell
as a working example. First the genome size is calculated for each
organism;Chlamydia has a genome size of 1.04Mb and theHomo
sapiens genome size is 3253.9Mb. The ratio of the Chlamydia
genome to the human genome is ∼1:3,200Mb, indicating that
chlamydial RNA will account for ∼0.03% of total host-bacteria
RNA. As ∼95% of this will be rRNA and tRNA (Westermann
et al., 2012), bacteria and host mRNA will account for ∼0.0015
and 4.9985% of total RNA, respectively. Given this ratio, 1 ×
1010 host reads and ∼3.33 × 109 bacterial reads are required
to capture sufficient RNA from both organisms. Thus, with the
majority of bacterial genomes falling within the range of ∼1–
5Mb, at least 1 × 1010 reads are needed for a successful dual
RNA-Seq experiment using bacteria-infected mammalian host
cells in order to achieve sufficient coverage.
Prior to sequencing, it should be considered whether single-
end (SE) or paired-end (PE) libraries should be prepared and
whether reads should be strand-specific. For dual RNA-Seq we
prefer paired-end reads where each RNA fragment is sequenced
from both sides, as it doubles the number of reads, reduces
the rate of alignment ambiguity, and enables the identification
of novel splice isoforms (host). Strand-specific libraries are also
recommended, as the usually high gene density and presence
of overlapping genes on opposite strands seen in bacterial
genomes can more accurately be measured, while allowing the
identification of potential antisense transcripts. The capture of
the entire transcriptome, including coding, non-coding, anti-
sense, and intergenic RNAs enables the discovery of complex and
global transcriptional events.
Infection
When infecting host cells, the bacterial MOI is an important
consideration—a suitable infection rate should be selected to
maximize the transcriptional response from both organisms
while minimizing the number of uninfected cells. Here we
describe the use of an MOI of ∼1.5 which allows for a ∼100%
infection; if additional measures are required to enrich the
selection of infected cells the researcher can consider increasing
the MOI, the sequencing depth, or physically separating infected
from infected cells by FACS or laser microdissection (Vannucci
et al., 2013; Westermann et al., 2016). However, caution is
recommended as an increased MOI can lead to a less biologically
relevant host response, while sequencing over a certain threshold
can promote transcriptional noise or spurious cDNA transcripts
(Tarazona et al., 2011).
The method of infection depends on the host cell and this
protocol provides guidance for infecting mammalian cell lines.
While the methodology is largely consistent for different cells,
the type of media and the required supplements will differ and
should be selected according to the host cell. Table 1 provides
a list of common cell types and their recommended culturing
conditions as a general guideline. As cycloheximide (an inhibitor
of protein synthesis often used to maximize chlamydial yields in
vitro), is not used, the host cells are seeded at ∼60% confluency
at the time of infection to ensure continued viability throughout
the time-course of the study. Given the time-sensitive nature of
the experiment, it is crucial to synchronize the initial bacterial
infection by centrifugation, followed by the removal of dead or
non-viable bacterial cells by washing twice with DPBS.
RNA Extraction
To ensure high-quality data, dual RNA-Seq typically requires
a relatively large amount of input RNA. Additionally, RNA
integrity is critical to the success of the protocol, as degraded
samples will result in low yields that are insufficient for
sequencing (Cheranova et al., 2013). Extreme care must be
taken to prevent DNA contamination or RNA degradation,
as this will be detrimental to both the library preparation
and subsequent analyses. Degradation can be minimized by
adhering to the protocol time and temperature requirements,
purchasing highly pure, and RNase-free reagents, and using
RNA-free equipment and consumables. Always conduct
RNA work in a clean environment that is partitioned from
non-RNA work.
There are several commercial kits available for performing the
RNA extraction (Table 2), but they differ in their effectiveness
and suitability for dual RNA-Seq. In our experience, the kits
that utilize bead disruption or column-based extraction suffer
from reduced yield and poor quality of the total host-bacteria
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TABLE 1 | Mammalian cell lines and culture medium.
Cell Line Cell Type Species Tissue Medium*
293 Fibroblast Human Embryonic kidney MEM and 10% FBS
3T6 Fibroblast Mouse Embryo DMEM, 10% FBS
A549 Epithelial Human Lung carcinoma F-12K, 10% FBS
A9 Fibroblast Mouse Connective tissue DMEM, 10% FBS
AtT-20 Epithelial Mouse Pituitary tumor F-10, 15% horse serum, and 2 .5% FBS
BALB/3T3 Fibroblast Mouse Embryo DMEM, 10% FBS
BHK-21 Fibroblast Hamster Kidney GMEM, 10% FBS, or MEM, 10% FBS, and NEAA
BHL-100 Epithelial Human Breast McCoy’5A, 10% FBS
BT Fibroblast Bovine Turbinate cells MEM, 10% FBS, and NEAA
Caco-2 Epithelial Human Colon adeno carcinoma MEM, 20% FBS, and NEAA
Chang Epithelial Human Liver BME, 10% calf serum
CHO-K1 Epithelial Hamster Ovary F-12, 10% FBS
Clone 9 Epithelial Rat Liver F-12K, 10% FBS
Clone M-3 Epithelial Mouse Melanoma F-10, 15% horse serum, and 2 .5% FBS
COS-1, COS-3, COS-7 Fibroblast Monkey Kidney DMEM, 10% FBS
CRFK Epithelial Cat Kidney MEM, 10% FBS, and NEAA
CV-1 Fibroblast Monkey Kidney MEM, 10% FBS
D-17 Epithelial Dog Osteosarcoma MEM, 10% FBS, and NEAA
Daudi Lymphoblast Human Blood from a lymphoma patient RPMI-1640, 10% FBS
GH1, GH3 Epithelial Rat Pituitary tumor F-10, 15% horse serum, and 2 .5% FBS
H9 Lymphoblast Human T-cell lymphoma RPMI-1640, 20% FBS
HaK Epithelial Hamster Kidney BME, 10% calf serum
HCT-15 Epithelial Human Colorectal adenocarcinoma RPMI-1640, 10% FBS
HeLa Epithelial Human Cervix carcinoma MEM, 10% FBS, and NEAA (in suspension, S-MEM)
HEp-2 Epithelial Human Larynx carcinoma MEM, 10% FBS
HL-60 Lymphoblast Human Promyeolocytic leukemia RPMI-1640, 20% FBS
HT-1080 Epithelial Human Fibrosarcoma MEM, 10% HI FBS, and NEAA
HT-29 Epithelial Human Colon adenocarcinoma McCoy’s 5A, 10% FBS
HUVEC Endothelial Human Umbilical cord F-12K, 10% FBS, and 100µg/mL heparin
I-10 Epithelial Mouse Testicular tumor F-10, 15% horse serum, and 2 .5% FBS
IM-9 Lymphoblast Human marrow from Myeloma patient RPMI-1640, 10% FBS
JEG-2 Epithelial Human Choriocarcinoma MEM, 10% FBS
Jensen Fibroblast Rat Sarcoma McCoy’s 5A, 5% FBS
Jurkat Lymphoblast Human Lymphoma RPMI-1640, 10% FBS
K-562 Lymphoblast Human Myelogenous leukemia RPMI-1640, 10% FBS
KB Epithelial Human Oral carcinoma MEM, 10% FBS, and NEAA
KG-1 Myeloblast Human Marrow from erythroleukemia patient IMDM, 20% FBS
L2 Epithelial Rat Lung F-12K, 10%FBS
LLC-WRC 256 Epithelial Rat Carcinoma Medium 199, 5% horse serum
McCoy Fibroblast Mouse Unknown MEM, 10% FBS
MCF7 Epithelial Human Breast adenocarcinoma MEM, 10% FBS, NEAA, and 10µg/mL insulin
WI-38 Epithelial Human Embryonic lung BME, 10% FBS
WISH Epithelial Human Amnion BME, 10% FBS
XC Epithelial Rat Sarcoma MEM, 10% FBS, and NEAA
Y-1 Epithelial Mouse Tumor of adrenal F-10, 15% horse serum, and 2.5% FBS
*BME, Basal Medium Eagle; DMEM, Dulbecco’s Modified Eagle Medium; FBS, Fetal Bovine Serum; GMEM, Glasgow Minimum Essential Medium; IMDM, Iscove’s Modified Dulbecco’s
Medium;MEM,Minimum Essential Medium; NEAA, Non-Essential Amino Acids Solution; TNM-FH, Trichoplusia ni Medium-Formulation Hink (i.e., Grace’s Insect Medium, Supplemented).
This table has been adapted from the Cell Culture Basics Handbook (ThermoFisher Scientific); for more information see: https://www.thermofisher.com/content/dam/LifeTech/global/
promotions/global/images/aai-2015/aai-pdfs/GibcoCellCultureBasicsHandbook.pdf.
RNA. Instead, we prefer the salt-precipitation protocol of
the MasterPureTM Complete DNA and RNA Purification Kit
(Epicenter) with optimized steps to be the most effective at
extracting quality RNA from several host-bacteria pairings.
The method of bacteria and host lysis is an important
consideration and will depend on the infection system being
investigated. We find that the enzymatic lysis included in the
MasterPureTM kit is most effective for lysing both host and
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TABLE 2 | Commercial RNA extraction kits.
Kit Catalog No. Manufacturer Lysis Method Extraction Method
RiboPure Bacteria AM1925 Ambion Bead cell disruption Spin column
PureLink RNA Mini Kit 12183020 Life Technologies Chemical lysis Spin column
RNeasy Mini Kit 74104 Qiagen Chemical lysis Spin column
MasterPure Complete DNA and RNA Purification Kit MC85200 Epicenter Chemical lysis Salt precipitation
UltraClean Microbial RNA Isolation 12224-50 MoBio Bead cell disruption Spin column
High Pure RNA Isolation Kit 11828665001 Roche Chemical lysis Spin column
Gram negative bacteria. For Gram positive bacteria, we include
an initial sonication step to break open the cell wall prior to
extraction. In each case, both the host and bacterial cells are
lysed, releasing endogenous RNases so it is critical to minimize
the delay between host cell lysis and RNA extraction to avoid
degradation. Host cells are lysed, host proteins digested, and
total nucleic acid precipitated with isopropanol. One caveat of
the MasterPure extraction kit is the residual contamination of
genomic DNA, however we have found that two treatments
with TURBO DNA-freeTM DNase (Thermo Fisher) is most
effective, compared to phenol:chloroform and precipitation-
based methods.
RT-PCR Quality Control
We recommend performing three real-time RT-PCR assays
for human targets and one endpoint PCR assay for bacterial
targets to confirm DNA removal and the presence of RNA.
These assays are based on TaqMan R© Gene Expression assays
(Applied Biosystems) with primer and probe sets targeting beta
actin, mitochondria-encoded ATP synthase 6, and eukaryotic
18S rRNA (Humphrys et al., 2013), and include a reverse
transcriptase-minus (RT-) test to detect contaminating DNA and
a reverse transcriptase-plus (RT+) test for the detection of RNA.
We generally base the endpoint PCR on custom-designed primer
sets that are specific for the bacterium of interest. Please consult
Table 3 for common problems and solutions relating to this stage.
rRNA Depletion
As rRNA typically constitutes more than 95% of total RNA,
rRNA depletion should be considered to maximize the recovery
of mRNA and reduce sequencing depth. It is possible to avoid
depletion steps by instead sequencing far more deeply and
subsequently removing rRNA reads during analysis. However,
the sequencing costs of this strategy are substantial, as most
sequence reads will align to rDNA genes and be discarded.
Further reductions of sequencing costs per base may permit
this strategy in the coming years, but it is currently more
cost-effective to deplete rRNA prior to sequencing. There
are several commercial kits available for nuclease digestion
and size-selection; this protocol utilizes both a hybridization-
based rRNA depletion and poly(A)-based depletion step. For
hybridization, cDNA oligonucleotides attach to complementary
rRNA that is immobilized on magnetic beads; always ensure
that the oligonucleotides are compatible with your organism(s)
of interest. For this, we combine an equivalent volume of
Ribo-Zero beads from both a Human/Mouse/Rat-specific and
Gram-negative bacteria-specific Ribo-ZeroTM rRNA Removal Kit
(Epicenter), enabling simultaneous reduction of both host and
bacterial rRNA. It is important to note that this method will not
enrich immature mRNAs or non-coding RNAs; specific target
enrichment techniques that are outside the scope of this protocol
should be considered if these are of experimental interest.
Aliquots of rRNA-reduced samples may be then subjected to
poly(A) depletion to further enrich host mRNA transcripts
and separate mRNA from rRNA. Poly(A)-depleted and rRNA-
depleted eluates can also be further purified before being
combined for library construction. As a guide, 1µg of input RNA
will yield <80 ng of rRNA-depleted RNA. The remaining RNA is
concentrated and purified with a RNAClean&ConcentratorTM-5
kit (Zymo Research).
Total rRNA-Depleted RNA Integrity and
Quantification
Prior to submission for sequencing, the RNA integrity, purity,
and concentration should be assessed, however dual RNA-
Seq experiments add additional complexity to the traditional
methods. Given that rRNA has been depleted, it is not
possible to properly visualize 28S and 18S rRNA banding
patterns following agarose gel electrophoresis to estimate
RNA integrity. However, low-molecular weight smearing
after running a small RNA sample from dual RNA-Seq
experiments on a gel is an early, yet imperfect indication
of possible RNA degradation. Spectrophotometric analysis,
usually with a Nanodrop instrument, is useful for estimating
RNA concentration and purity where readings are taken at a
wavelength of 260 nm and the ratio of A260/A280 readings are
measured. As a guide, an A260 of 1.0 is equivalent to about
40µg/mL of RNA. The A260/A280 ratio is a measurement of
protein contamination in the sample, where pure RNA should
have a ratio of ∼2.0. Note, however, that this method can
suffer from low accuracy and biases introduced by protein
contamination (Baelde et al., 2001).
A Bioanalyzer (Agilent) is usually regarded as the gold
standard for estimating RNA quality by calculating an RNA
integrity number (RIN), an estimation of RNA degradation
which ranges from 1 to 10, with 10 being the least-degraded
and most quality RNA. However, the mixture of eukaryotic
and prokaryotic RNA in a dual RNA-Seq sample confounds the
RIN measurement and a reliable number cannot be obtained.
Instead, the Bioanalyzer electropherogram is useful to detect the
presence of carry-over rRNA and RNA degradation. For RNA
quantification with the Bioanalyzer we generally use an RNA
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TABLE 3 | Troubleshooting.
Stage Problem Cause Solution
Nanodrop A260/A280 ratio is <1.8 This indicates protein contamination
in the sample. The cell lysis and
purification steps were not effective
Decrease the amount of starting
material. Use fresh proteinase K;
ensure the correct concentration.
Increase incubation time or
concentration to 100 ug/mL if
necessary.
Agarose gel electrophoresis Two large, prominent bands on gel These are potentially the 18S and
28S eukaryotic rRNA indicating that
rRNA-depletion was not effective
Low molecular weight smearing RNA is potentially degraded Run on Bioanalyzer to confirm.
Bioanalyzer Two large peaks at ∼30 s Potentially the 18S and 28S
eukaryotic rRNA indicating that
rRNA-depletion was not effective
Well-defined peaks at ∼15 s Potentially the tRNA and miRNA Columns were not effective to remove
small size fragments.
Low-molecular weight peaks RNA is potentially degraded Ensure work is conducted in an
RNase-free environment. Avoid
freeze-thawing RNA.
Low, wide peak at ∼30 s Potential DNA carryover Increase DNase incubation time.
RNA elution Low RNA yield If not degraded, RNA extraction may
not have been effective.
Do not freeze-thaw RNA. Increase
number of cells. Increase lysis
incubation time.
Cell lysis may be incomplete Repeat incubation in cell lysis buffer if
necessary. For systems that include
Gram positive bacteria, ensure that
the sonication step is performed to
complete, with incubation on ice
between each pulse.
RNA purification Loose pellet Pellet not completely dried.
Centrifugation not effective
Dry sample on ice before adding
Protein Precipitation Reagent. Repeat
centrifugation step.
RT-PCR Amplification in RT- control gDNA contamination Confirm the integrity of DNase used.
Increase incubation time. Ensure that
the cell lysis procedure was correctly
followed.
Weak amplification product Degraded reagents Avoid freeze-thawing template and
reagents. Check the expiry of the
reagents. Input template may be too
concentrated or too dilute.
Degraded template
No cDNA synthesis Reduce the temperature for the cDNA
synthesis step. Annealing temperatur
mnay be too high. Increase the
extension time and number of cycles.
6000 ladder as the reference and prefer to use RNA 6000 pico
chips as the nanochips tend to suffer from reduced sensitivity.
However, note that the accuracy of the assay will decrease if the
maximum RNA concentration is exceeded for the chip. Please
consult Table 3 when troubleshooting RNA quantification steps.
Library Preparation and Sequencing
When preparing RNA for NGS, the broad steps include
fragmentation and/or size selection, conversion to cDNA,
adapter attachment, and quantification. NGS is a rapidly
expanding field and there are currently a number of sequencing
platforms currently available, including Illumina, SOLiD, Ion
Torrent, Roche 454, Oxford Nanopore, and Pacific Biosciences,
with specific advantages and library preparation kits associated
with each. When deciding on a sequencing technology, the
defining objective of the experiment should be considered; i.e., is
the focus on all transcriptional events (coding, non-coding, anti-
sense, and intergenic RNAs), just the coding mRNA transcripts,
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or just small RNAs (miRNA, snoRNA, snRNA; Head et al.,
2014). Long-read sequencing offered by PacBio and Nanopore
can often span full-length transcripts to provide a more accurate
measurement of isoform structures, while Oxford Nanopore can
directly sequence RNA, removing the requirement for cDNA
conversion. However, more traditional technologies such as
Illumina and Ion Torrent can generally provide more accuracy.
This stage of the experiment is not specific to (dual) RNA-Seq
and is usually outsourced to commercial enterprise or central
sequencing facility, with each providing their own detailed
instructions for sample preparation so the steps are outside
the scope of this protocol. Nevertheless, here we provide some
general guidelines based on our experience.
We generally use the TruSeq Sample Prep Kit for library
preparation and sequencing by the Illumina platform. For
this, the mRNA is chemically fragmented and primed with
random hexamer primers. First-strand cDNA synthesis occurs
using reverse transcriptase, followed by second strand cDNA
synthesis using DNA polymerase I and RNase H. The cDNA
is purified and end-repaired and 3′ adenylated. Adapters
containing six nucleotide indexes are ligated to the double-
stranded cDNA, which is purified with AMPure XT beads
(Beckman Coulter) and enriched via polymerase chain reaction
(PCR) amplification. Paired-end reads >50 nucleotides will
promote increased fragment randomization; longer reads will
enable greater coverage, reduced multi-mapping, and improved
transcript identification (Garber et al., 2011); we recommend
paired-end 100 bp reads.
Bioinformatics Analysis
The latter stages of a dual RNA-Seq experiment are the key
statistical and bioinformatic analyses that underlie the inference
of biological knowledge. The difficulties of dealing with both
prokaryotic and eukaryotic transcriptional data extend to these
steps and several strategies have been developed to ensure
meaningful data can be produced. While a brief overview
is provided here, the researcher is encouraged to consult
the detailed bioinformatic pipeline that has been published
previously (Marsh et al., 2017).
Raw sequences are usually provided from the sequencing
facility in FASTQ format, which can initially be subjected
to contamination detection with FastQ Screen (www.
bioinformatics.babraham.ac.uk/projects/fastq_screen/) to
ensure that the majority of reads are derived from the two
organisms of interest. This is followed by an assessment of read
quality with FASTQC (www.bioinformatics.babraham.ac.uk/
projects/fastqc/) and the use of Trimmomatic (Bolger et al., 2014)
to remove low-quality reads and sequencing adapters. HISAT2
(Kim et al., 2015) is used for mapping and alignment, where total
host-bacteria reads are mapped to the host reference genome,
while unmapped (bacterial) reads are subsequently mapped to
the bacterial reference genome with Bowtie2 (Langmead et al.,
2009). We use HTSeq (Anders et al., 2015) or featureCounts
(Liao et al., 2014) for read counting, where aligned sequences
are quantified as an exon, transcript, gene etc., which results
in a separate count matrix for host and pathogen reads, each
consisting of genes (rows) and samples (columns). A key
step prior to statistical analysis is data normalization. There
are several normalization strategies available; we prefer the
trimmed mean of M-values (TMM) method for both host and
bacterial reads, which provides between-sample normalization
while correcting for variations in sequencing depth and sample
variation (Robinson and Oshlack, 2010).
For the actual data analysis, there are two distinct strategies for
representing host and bacterial counts. For the host, genes that
are differentially expressed between infected and non-infected
controls are identified using packages such as edgeR, Kallisto,
Limma, DESeq2, or Cufflinks, where we prefer the Limma
package for dual RNA-Seq due to its ability to manage sample
variation between conditions and time-points (Robinson et al.,
2010; Trapnell et al., 2012; Love et al., 2014; Ritchie et al., 2015;
Bray et al., 2016). This results in a list of DEGs, which are
subjected to a false discovery rate (FDR) cutoff of <0.05 and
a log fold-change (LFC) cutoff of at least 2-fold upregulation
or downregulation. For the bacterial data, counts are subjected
to within-sample normalization and reported as transcripts-per-
million (TPM) which incorporates gene length information to
provide a measurement of relative transcript abundance.
MATERIALS AND EQUIPMENT
Reagents
Mammalian cells and associated media CRITICAL All
experiments that use human or animal tissues must comply with
governmental and institutional guidelines and regulations.
Bacterial species of interest CAUTION Many bacteria are
human pathogens that pose a risk of infection. All work with this
organism should be conducted in a class II biosafety cabinet while
wearing appropriate personal protective equipment (PPE).
Ethanol (Sigma-Aldrich, cat. no. E7023) CAUTION Highly
flammable. Causes skin and serious eye irritation. Handle using
appropriate safety equipment.
Isopropanol (Sigma-Aldrich, cat. no. I9516)
Poly(A)Purist Mag Purification Kit (Thermo Fisher, cat. no.
AM1922)
TURBO DNA-freeTM kit (Thermo Fisher, cat. no. AM1907)
DEPC-treated water (Thermo Fisher, cat. no. AM9915G)
MasterPureTM Complete DNA and RNA Purification Kit
(Epicenter, cat. no. MC85200)
RNA Clean & ConcentratorTM-5 (Zymo Research, cat. no.
R1015)
Ribo-ZeroTM rRNA Removal Kit (Human/Mouse/Rat)
(Epicenter, cat. no. RZH1046)
Ribo-ZeroTM rRNA Removal Kit (Gram-negative bacteria)
(Epicenter, cat. no. RZNB1056)
Sonicator S-4000 (Misonix, cat. no. S4000) (for use when
lysing Gram positive bacteria)
TaqMan R© Gene Expression Assay (Thermo Fisher, cat. no.
4453320)
High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher, cat. no. 4368814)
Beta actin probe (Thermo Fisher, cat. no. Hs99999903_m1)
Mitochondrially encoded ATP synthase 6 probe (Thermo
Fisher, cat. no. Hs02596862_g1)
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Eukaryotic 18S rRNA probe (Thermo Fisher, cat. no.
Hs99999901_s1)
Equipment
MicroAmp R© optical 96-well reaction plates (Thermo Fisher, cat.
no. 4306737)
MicroAmp R© optical adhesive film (Thermo Fisher, cat. no.
4311971)
MicroAmp R© optical film compression pad (Thermo Fisher,
cat. no. 4312639)
Flask rocker (Grant Instruments, PS-M3D)
DNase and RNase-free 1.5 mL microcentrifuge tubes
(Sarstedt, cat. no. 72.692.210)
Refrigerated microcentrifuge (Beckman Coulter, 20R)
Centrifuge (Beckman Coulter, X-12R)
Vortex (Scientific Industries, G-560E)
Heating block (x2) (Thermo Fisher, cat. no. 2001Q)
Ice
Ice bucket
Timer
Real-time qPCR machine (Applied Biosystems, 7900HT)
Temperature cycler (Bio-Rad, C1000)
Incubator, 37◦C, 5% CO2 (Sanyo, MCO-19AIC)
Bioanalyzer
RNA 6000 Pico Kit (Agilent, cat. no. 5067-1513)
6-well plates (Thermo Scientific, cat. no. 140675)
Cell scrapers (Sarstedt, cat. no. 83.1830)
15 mL centrifuge tubes (Thermo Scientific, cat. no. 339652)
Reagent Setup
70% ethanol Combine 350mL ethanol with 150mL nuclease free
water. Store at room temperature for up to 6 months.
Ribo-ZeroTM rRNA Removal Kit The Ribo-Zero kits are
composed of two parts: the magnetic core kit and the rRNA
removal reagents. Store the magnetic core kits at 4◦C and
Mouse/Human/Rat and Gram-negative bacteria rRNA removal
reagents at−80◦C.
RNAClean & ConcentratorTM-5 Add 48 mL of 100% ethanol
to the 12 mL RNAWash Buffer before use.
PROCEDURES
Seeding and Infection
1. Seed × 105 mammalian host cells per well in all wells of a
six-well plate. Ensure there are two plates per time-point (one
infected plate and one non-infected control plate). Incubate
plates overnight at 37◦C, 5% CO2.
Following seeding, sit plates on a bench at room temperature for
15 min to allow cells to settle, ensuring an even distribution of
cells.
The next day, the cells should be evenly distributed throughout
the well.
2. The next day, infect all plates (except mock-infected control
plates) at an MOI of 1.5 to ensure that 100% of the host cells
will be infected.
Rock plates for 30 mins on shaker.
3. Centrifuge plates at 500 × g for 30 min at room temperature.
Incubate plates at 37◦C, 5% CO2, according to time-point.
Centrifugation is important to synchronize the infections and
time-points and ensure an MOI of 1.5.
4. Wash cells twice with DPBS and overlay with warm, fresh
media. Incubate at 37◦C, 5% CO2.
Harvesting Cells (30 Min)
5. At each time-point, wash cells twice with ∼3 mL DPBS and
add 1 mL DPBS to each well. Harvest cells with a cell scraper
and dispense solution into a 15 mL centrifuge tube.
Ensure all cells are collected from each well. It may be beneficial
to add a second 1 mL of DPBS to collect any remaining cells.
Store tubes at−80◦C until all time-points are complete. Cells can
be stored for up to 6 weeks at−80◦C.
PAUSE POINT
Cell Lysis (45 min)
6. Remove centrifuge tubes from −80◦C freezer and thaw at
room temperature.
7. Pre-set heating block to 65◦C.
8. Add 1 µL of 50µg/mL Proteinase K (MasterPureTM
Complete DNA and RNA Purification Kit; Epicenter) to 300
µL of Tissue and Cell Lysis Buffer (MasterPureTM Complete
DNA and RNA Purification Kit; Epicenter) for each
sample.
9. Pellet cells by centrifugation at 5,000× g for 30 min. Discard
the supernatant, leaving∼25 µL of liquid.
10. Vortex for 10 s to resuspend the pellet.
11. Add 300 µL of Tissue and Cell Lysis Solution (containing
Proteinase K) to each 25 µL sample and mix thoroughly by
vortexing.
12. For systems containing Gram positive bacteria:
Set sonicator to an amplitude setting of 10 and perform six
treatments of 30 s each to disrupt the cells. Place tubes on ice for
30 s between each treatment.
Incomplete sonication can lead to a reduction in bacterial
RNA yield.
13. For all systems:
Incubate tubes in a heating block at 65◦C for 15 min, vortexing
briefly every 5 min.
The solution should become cloudy as cells are lysed and
proteins are digested.
14. Place samples on ice for 3–5 min.
Total Nucleic Acid Precipitation (1 h)
15. Add 175 µL of MPC Protein Precipitation Reagent
(MasterPureTM RNA Purification Kit; Epicenter) to each 300
µL of lysed sample and vortex vigorously for 10 s.
16. Pellet the debris by centrifugation at 10,000 × g for 10 min
at 4◦C.
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You should see a clear pellet of cellular debris. If not, vortex
briefly, incubate at room temperature for 10 mins and centrifuge
again.
17. Transfer the supernatant (containing total nucleic acid)
to a clean 1.5 mL microcentrifuge tube and discard the
pellet.
18. Add 500µL of isopropanol to the recovered supernatant and
invert the tube 30–40 times. Do not vortex.
Isopropanol will desalt and precipitate the nucleic acid. It may be
beneficial to mark the side of the tube prior to centrifugation as
pellets from isopropanol treatment have a glassy appearance that
may be difficult to see.
19. Pellet the total nucleic acid by centrifugation at 10,000 × g
for 10 min at 4◦C.
20. Carefully pour off the isopropanol without dislodging the
pellet.
Pellets from isopropanol treatment are loosely attached and care
should be taken when pouring.
21. Rinse the pellet twice with 70% ethanol, being careful not to
dislodge the pellet. Centrifuge briefly if pellet is dislodged.
Ethanol is more volatile than isopropanol and will make the DNA
easier to dissolve. Perform at room temperature.
22. Remove residual ethanol with a pipette and resuspend the
pellet in 35µL of TE Buffer (MasterPureTM RNA Purification
Kit; Epicenter). Samples can be stored in TE Buffer overnight
at 4◦C.
PAUSE POINT
DNA Digestion (45 min)
23. Pre-set heating block to 37◦C.
24. Add 4 µL of 10x TURBO Dnase Buffer (TURBOTM DNA-
freeTM Kit; Thermo Fisher) to each 35 µL sample.
25. Add 1 µL of TURBOTM DNase to each sample. Gently flick
the tubes to mix and briefly centrifuge to distribute liquid to
the bottom of the tube.
Increase DNase volume to 2-3 µL if digesting a higher amount of
DNA. Alternatively, add half theDNase to each reaction, incubate
for 30 min, then add the remainder of the enzyme and incubate
for another 30 min.
26. Incubate tubes in a heating block at 37◦C for 30 min.
27. After incubation, add 8 µL of DNase Inactivation Solution
(TURBOTM DNA-freeTM Kit; Thermo Fisher) and incubate
tubes at room temperature for 5 min. Mix occasionally by
manually inverting.
Environments colder than 22◦C can reduce the inactivation of
TURBOTM DNase. Move tubes to a heating block to control the
temperature if necessary.
28. Centrifuge tubes at 10,000× g for 1.5 min.
29. Transfer supernatant (containing the RNA) to a fresh 1.5 mL
microcentrifuge tube.
The pellet should be visible; if not, vortex briefly and repeat
centrifugation for 5 mins. Take care not to dislodge the pellet
when pouring.
PAUSE POINT
Validation of DNA Removal by RT-PCR (2h)
30. Remove 5µL from each RNA sample and place in a clean 1.5
mL microcentrifuge tube.
Keep all samples and reactions on ice.
31. Add 95 µL of nuclease-free water (1:20 dilution).
32. Prepare a 2X RT master mix for each sample in triplicate.
Include a non-template control and an RT- control.
10X RT buffer: 2 µL
25X dNTP mix (100mM): 0.8 µL
10X RT random primers: 2 µL
RNase inhibitor: 1 µL
RNA-free dH2O: 3.2 µL
33. Prepare 1X reactions (20 µL total) by combing the 2X
master mix with the following in individual wells of a 96-well
reaction plate (Thermo Fisher):
Reaction 1: 10 µL sample+ 2 µL RT+ 1 µL dH2O
Reaction 2: 10 µL sample+ 3 µL dH2O
Reaction 3: 11 µL dH2O+ 2 µL RT
Gently pipette up and down to mix.
Seal the plate.
34. Briefly centrifuge plate to spin down the solution and
eliminate any air bubbles.
35. Perform the reverse transcription reaction according to the
following conditions:
25◦C, 10 min
37◦C, 120 min
85◦C, 5 min
cDNA can be stored at −20◦C. Create small aliquots to prevent
degradation resulting from frequent freeze-thawing.
36. Run 20 µL of each reaction on a 1% agarose gel and examine
under UV fluorescence.
There should be large bands in the lane containing Reaction 1,
indicative of cDNA. The lane containing Reaction 2 should be
free of bands, otherwise contamination with gDNA has occurred.
The lane containing Reaction 3 should also be free of bands. See
Table 3 for troubleshooting options.
Confirm Presence of RNA by RT-PCR
37. Make a 1:20 dilution of cDNA, prepared above.
38. Prepare enough RT-PCR master mix to assay each sample in
triplicate, as well as controls.
20x TaqMan R© Gene Expression Assay: 1 µL
2x TaqMan R© Gene Expression Master Mix: 10 µL
RNase-free water: 5 µL
39. Cap the tube and invert the tube several times to mix the
reaction components. Pulse vortex.
40. Aliquot 15µL ofmastermix into individual wells of a 96-well
reaction plate (Thermo Fisher). Include a triplicate reaction
for each sample and non-template controls.
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41. Add 4 µL of each diluted template to appropriate wells and
gently tap plate on benchtop to distribute contents to the
base of the well.
42. Place adhesive film (Thermo Fisher) over the plate and seal
with compression pad (Thermo Fisher).
If any bubbles are visible in the wells or liquid is present on the
sides of the wells, centrifuge plate at 500 × g for 2 min. Do not
touch the film with ungloved hands at any point.
43. Place plate in RT-PCR machine and run assay according to
the following cycling conditions:
Hold: 95◦C, 10 min
Cycle (40x): 95◦C, 15 s
60◦C, 1 min.
Amplification curves should be present for all targets,
representing the accumulation of product throughout the
RT-PCR experiment. Ensure that the amplification signal is
at least ten times the baseline standard deviation to indicate
amplification over noise. See Table 3 for additional guidelines.
PAUSE POINT
rRNA Depletion (90 min)
44. Pre-set one heating block to 68◦C and one at 50◦C.
45. Remove Ribo-ZeroTM rRNA Removal Magnetic Core Kit
from 4◦C and allow to warm to room temperature.
Remove Human/Mouse/Rat and Gram-negative bacteria
components of the Ribo-ZeroTM rRNA Removal kits from
−80◦C and thaw on ice.
Do not place the Ribo-ZeroTM Magnetic Core Kit on ice as this
can damage them and reduce the efficiency of the procedure.
46. Vigorously mix magnetic beads (Ribo-ZeroTM rRNA
Removal kit; Illumina) for 20 s by vortexing.
47. Carefully pipette 65 µL of magnetic beads into 2 mL
microsphere wash tubes (Ribo-ZeroTM rRNA Removal kit;
Illumina); two tubes per sample.
Dispense magnetic beads slowly to avoid introducing air bubbles.
Store unused beads at 4◦C. Do not place the magnetic beads on
ice.
48. Open tube cap and place on magnetic stand for 2 mins.
At this stage the liquid should become clear.
49. Centrifuge microspheres at 12,000 × g for 3 min. Carefully
remove supernatant without dislodging the pellet.
HAZARD: The supernatant contains sodium azide.
50. Wash the microsphere wash tubes by adding 130 µL of
microsphere wash solution (Ribo-ZeroTM rRNARemoval kit;
Illumina) to each tube. Vortex vigorously.
51. Centrifuge microsphere wash tubes at 12,000 × g for 3 min.
Carefully remove supernatant without dislodging the pellet.
52. Add 65 µL of microsphere resuspension solution
(Ribo-ZeroTM rRNA Removal kit; Illumina) to each
tube and vortex vigorously until a homogenous suspension
is produced.
53. Add 1 µL of RiboGuard RNase inhibitor (Ribo-ZeroTM
rRNA Removal kit; Illumina) to each tube. Mix by vortexing
for 10 s and set aside (at room temperature).
Avoid creating air bubbles when adding RNase inhibitor.
54. Treat two aliquots of each sample with Ribo-Zero rRNA
removal solution (Ribo-ZeroTM rRNARemoval kit; Illumina)
according to the following preparation (two removal preps
per sample):
RNase-free water (Ribo-ZeroTM rRNA Removal Kit): 1 µL
Ribo-Zero Reaction Buffer: 4 µL
RNA sample: 25 µL
Ribo-Zero rRNA Removal Solution (Gram negative bacteria
kit): 5 µL
Ribo-Zero rRNA Removal Solution (Human/Mouse/Rat
kit): 5 µL
Fully mix the samples by pipette-mixing 10-15 times.
The beads may clump at this stage due to the biotin on the
probes binding to multiple beads. If so, vortex for at least 10 s.
55. Incubate at 68◦C for 10 min in heating block. Return the
Ribo-Zero reaction buffer to−80◦C.
56. Remove the microsphere wash tubes from the heating block
and incubate at room temperature for 15min.
57. Vortex the microsphere wash tubes at medium speed for 20 s
to ensure a homogenous slurry.
58. Pipette hybridized RNA sample to the resuspended
microsphere wash tubes, pipette-mixing 10–15 times to mix.
Immediately vortex the microsphere wash tubes at medium
speed for 5 s.
The washed magnetic beads must be at room temperature for use
in this step. The order of the addition (hybridized RNA to the
magnetic beads) is critical for rRNA removal efficiency.
59. Incubate microsphere wash tubes at room temperature for
10 min. Vortex at medium speed for 5 s, every 3–4 min.
60. Following incubation, mix samples again by vortexing at
medium speed for 5 s.
61. Incubate samples in heating block at 50◦C for 10 min.
62. Transfer the RNA-microsphere suspension to a Microsphere
Removal Unit (Ribo-ZeroTM rRNA Removal kit; Illumina)
and centrifuge at 12,000× g for 1 min at room temperature.
Save the eluate and discard the removal unit.
At this stage, the eluate should be∼100 µL.
Probe and rRNA contamination can occur if magnetic beads
are allowed to carry over.
PAUSE POINT
Purification of rRNA-Depleted Samples
(45 min)
63. Add 2 volumes of RNA Binding Buffer (RNA Clean &
ConcentratorTM-5; Zymo Research) to each volume of RNA
sample and mix well.
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Theminimum recommended sample volume for use with this kit
is 50 µL.
64. Add 1 volume of 100% ethanol to the mixture and mix well.
65. Transfer the mixture to a Zymo-Spin IC column (RNA
Clean & ConcentratorTM-5; Zymo Research) in a collection
tube and centrifuge at 12,000 × g for 1 min. Discard the
flow-through.
66. Combine two reactions of the same sample to one column
and spin multiple times until the entire mixture passes
through the column. The column capacity is 5 µg of RNA.
67. Add 400 µL of RNA Prep Buffer (RNA Clean &
ConcentratorTM-5; Zymo Research) to the column and
centrifuge at 12,000× g for 1 min. Discard the flow-through.
68. Add 800 µL of RNA Wash Buffer (RNA Clean &
ConcentratorTM-5; Zymo Research) to the column and
centrifuge at 12,000× g for 1 min. Discard the flow-through.
69. Add 400 µL of RNA wash buffer to the column and
centrifuge at 12,000× g for 1 min. Discard the flow-through.
70. Centrifuge the column in an emptied collection tube at
12,000 × g for 2 min. Carefully remove the column
from the collection tube and transfer to a new RNase-free
microcentrifuge tube.
71. Add 20 µL of DNase/RNase-free water directly to one
columnmatrix and let stand for 10min at room temperature.
Centrifuge at 10,000× g for 30 s.
Repeat elution.
The eluted RNA can be used immediately or stored at−80◦C.
PAUSE POINT
Check RNA Quality and Quantity
72. Make a 1:20 dilution of eluted RNA.
73. Run on a 2% agarose gel with an appropriate molecular
weight marker.
Large, clear bands are likely to be rRNA, indicating that
rRNA depletion was not successful. Look for low molecular
weight smearing which will indicate RNA degradation. High(er)
molecular weight smearing (>∼400 bp) will be the eluted RNA
and can be expected. See Table 3 for troubleshooting options.
74. Measure the quality and quantity of eluted RNA by assaying
a 1 µL on a Nanodrop instrument. Observe absorbance
readings at 260 nm, as well as the A260/A280 ratio.
The RNA concentration should be sufficient for the sequencing
requirements (check the sample submission guidelines for
the sequencing technology that will be used). An A260
of 1.0 is equivalent to about 40µg/mL of RNA. The
A260/A280 ratio is a measurement of protein contamination
in the sample, where pure RNA should have a ratio
of∼2.0.
75. Measure the quantity and integrity of RNA on a Bioanalyzer
instrument. Consult the manufacturer’s guidelines for the
assay: http://www.genomics.agilent.com/en/Bioanalyzer-
System/2100-Bioanalyzer-Instruments/?cid=AG-PT-106
If carryover rRNA is present, the electropherogram will produce
two distinct peaks corresponding to 18S and 28S eukaryotic
rRNA (and possibly 16S and 23S prokaryotic rRNA, but these
cannot be differentiated from the eukaryotic rRNA peaks),
indicating that rRNA-depletion was not successful. Degraded
RNA can be identified by any peaks appearing at the lower
part of the electropherogram, which highlights a distribution
shift toward smaller RNA fragments. See Table 3 for additional
troubleshooting steps.
PAUSE POINT
Library Preparation and Sequencing
The method of library preparation is dependent on the
sequencing platform used and thus is outside the scope of this
protocol. Commercial sequencing enterprises and sequencing
centers will provide detailed guidelines on the library preparation
and sample submission guidelines that begin with the isolation
of pure mRNA as described above. Following sequencing, the
user will be provided with a series of raw FASTQ sequence files
that serve as the input for the subsequent computational data
analysis.
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